Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Decreases By 49.0%

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a significant drop in short interest in February. As of February 15th, there was short interest totalling 47,200 shares, a drop of 49.0% from the January 31st total of 92,500 shares. Based on an average daily trading volume, of 625,500 shares, the days-to-cover ratio is currently 0.1 days.

Astellas Pharma Stock Down 0.6 %

ALPMY opened at $9.71 on Friday. Astellas Pharma has a fifty-two week low of $9.05 and a fifty-two week high of $13.14. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.80 and a current ratio of 1.04. The company has a market capitalization of $17.57 billion, a P/E ratio of -44.13 and a beta of 0.34. The stock has a fifty day moving average of $9.62 and a 200-day moving average of $10.76.

Astellas Pharma (OTCMKTS:ALPMY) last posted its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. On average, equities analysts expect that Astellas Pharma will post 0.42 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.